News
What’s happening in NF1 research today
Data made available for Research Tools that Accelerate Development of Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas
For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems. Slow growing histologically benign tumors such as neurofibromas are challenging to grow in typical culture conditions. As […]
Data Available to Accelerate Development of Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas
For Release: October 2018 Neurofibromas are tumors of the nerve that are found most commonly in people with neurofibromatosis type I (NF1). NF1 is a neurogenetic disease with an estimated prevalence of 1/2500-1/3000. A type […]
Data made available for a 3D model of Neurofibromatosis Type 1 Plexiform Neurofibromas
For Release: October 2018 Development of therapies for human disease remains dependent on well-characterized and validated model systems for pre-clinical therapeutic testing. Most in vitro drug testing is performed on cells growing in two dimensions […]
Two New Clinician-Scientists Chosen for Neurofibromatosis Award, Research Support
Author: Cathy Gara. July 2018–The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Shruti Garg, of the University of Manchester, and Dr. Ina Ly, […]
Funding Available for Neurofibromatosis Research from the Department of Defense – Congressionally Directed Medical Research Programs
The FY18 Neurofibromatosis Research Program (NFRP) is accepting applications for research projects. Applications to the Fiscal Year 2018 (FY18) Neurofibromatosis Research Program (NFRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development […]
Cutaneous Neurofibromas Initiative Outlines Current Biology and Path Forward for Clinicians and Scientists
July 10, 2018: One of the hallmarks of the complex syndrome Neurofibromatosis type 1 (NF1) are cutaneous neurofibromas (cNF). cNF are tumors involving the skin that affect up to 99 percent of adults with NF1. […]
New Research Tools Available in the Search for Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas
New Research Tools Available in the Search for Therapies for Neurofibromatosis Type 1 Plexiform Neurofibromas By Cathy Gara | For Release: June 15, 2018 Plexiform neurofibromas affect up to 50 percent of people with neurofibromatosis […]
NTAP announces Dr. Angela Hirbe (Washington University) and Dr. Ping Chi (Memorial Sloan Kettering Cancer Center) have been selected as the 2017 recipients of the Francis S. Collins Scholars Award in Neurofibromatosis Clinical and Translational Research
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at The Johns Hopkins School of Medicine is proud to announce that Dr. Angela Hirbe (Washington University) and Dr. Ping Chi (Memorial Sloan Kettering Cancer Center) have been selected […]
Cutaneous Neurofibroma Initiative Projects (2018)
9 Projects Transforming the Field of NF1 Research NTAP convenes symposiums on a regular basis to determine research priorities, define new avenues of inquiry and develop requests for applications (RFAs) in neurofibromatosis type-1 (NF1) research […]
NTAP 2018 Cutaneous Neurofibroma Initiative: 4 Supplement Paper summaries
As a result of the 2018 Cutaneous Neurofibroma Initiative, several working groups were formed to produce papers addressing key challenges identified. Those papers are summarized below with links to the full papers provided. This information […]
NTAP and CTF supported early-phase trial demonstrates shrinkage in pediatric neural tumors
Bethesda, MD (December 28, 2016) NCI Press Release: In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the […]
NTAP Announces latest Francis S. Collins Scholar, Dr. Ashley Cannon
Baltimore, MD (January 3, 2017) Ashley Cannon, Ph.D., M.S., has been named the 2016 winner of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program […]